| Literature DB >> 35086494 |
Jacqueline Watt1, Jessica Fitzpatrick1, Stephen M Sozio2,3,4, Bernard G Jaar2,3,4,5, Michelle M Estrella6,7, Larisa G Tereshchenko2,8, Jose M Monroy-Trujillo2, Michael Walsh9,10,11, Rulan S Parekh12,13,14,15.
Abstract
BACKGROUND: Patients receiving intermittent hemodialysis have variable times of recovery to feeling better after dialysis. QT prolongation, a precursor to clinical and subclinical cardiovascular events, may contribute to delayed recovery time. We hypothesized that abnormal electrocardiographic parameters indicating perturbations in ventricular action are associated with longer recovery times thus impacting a patient-centered quality of life.Entities:
Keywords: Arrhythmias; Dialysis; ESRD; Electrocardiography; Hemodialysis; Incident; QT interval; QTc; Recovery time; Sudden cardiac death
Mesh:
Year: 2022 PMID: 35086494 PMCID: PMC8796483 DOI: 10.1186/s12882-022-02664-3
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristics of the PACE study cohort (2009–2012)
| Characteristics | Normal QTc | Prolonged QTca | Overall |
|---|---|---|---|
| Age (years) | 54 (16) | 55 (13) | 55 (13) |
| Male | 16 (40%) | 117 (58%) | 133 (55%) |
| African American | 29 (73) | 146 (72%) | 175 (72%) |
| PHQ-9 Total Depression Score | 4 (1, 7) | 4 (1, 8) | 4 (1, 8) |
| QT Interval (ms) | 415.0 (29.3) | 459.9 (48.0) | 452.5 (48.4) |
| QTc (ms) | 433.8 (19.5) | 498.9 (43.1) | 488.1 (46.9) |
| QRST Angle (degrees) | 7.2 (5.2) | 9.3 (4.4) | 9.0 (4.6) |
| Heart Rate (ms) | 92.2 (13.5) | 85.7 (13.4) | 86.8 (13.6) |
| Heart Rate Variance (ms2) | 350.9 (107.4, 1103.8) | 640.5 (202.7, 1840.5) | 380.3 (128.8, 1228.9) |
| LVHc | 5 (12.8%) | 27 (14.8%) | 32 (14.5%) |
| LVMId (g/m2) | 134.7 (52.6) | 140.5 (45.0) | 139.5 (46.3) |
| CRP (μg/mL) | 3.2 (1.6, 7.4) | 6.4 (2.6, 15.0) | 5.8 (2.4, 14.9) |
| Diabetes | 17 (43%) | 121 (60%) | 138 (57%) |
| RAASb | 17 (46%) | 81 (44%) | 98 (44%) |
| Beta Blockers | 21 (53%) | 131 (65%) | 152 (63%) |
| Alpha-Blocker, Calcium Channel Blocker, Vasodilator | 31 (84%) | 142 (77%) | 173 (78%) |
| Diuretic | 4 (11%) | 46 (23%) | 50 (23%) |
| Congestive Heart Failure | 15 (38%) | 82 (41%) | 97 (40%) |
| Charlson Comorbidity Index | 3 (2, 5) | 4 (3, 6) | 4 (3, 6) |
| Baseline Length of Hemodialysis Treatment | 215.5 (24.0) | 215.9 (19.7) | 215.9 (20.3) |
| Interdialytic Weight Gain | 1.8 (0.6) | 2.2 (0.9) | 2.1 (0.9) |
| Use of QT Prolonging Medicationse | 11 (28%) | 74 (37%) | 85 (35%) |
| Non-dialysis Seated Systolic Blood Pressure | 129.9 (20.7) | 137.6 (25.6) | 136.4 (25.0) |
| Non-dialysis Seated Diastolic Blood Pressure | 69.4 (14.0) | 74.6 (13.7) | 73.7 (13.8) |
| Recovery Time (min) | 10 (7.5, 30) | 30 (10, 120) | 20 (10, 60) |
a Defined as > 440 ms for males and > 460 ms for females [26]
b Renin-angiotensin-aldosterone system blockades
c Left ventricular hypertrophy defined using the Cornell voltage product [20]
d Left ventricular mass index
e QT prolonging medications include furosemide, ritonavir, sertraline, trazodone, escitalopram, tramadol, esomeprazole, pantoprazole, lansoprazole, and metoclopramide
Fig. 1ECG measurements over recovery time in minutes, model includes recovery time and one of the main exposures. A The distribution of QTc interval lengths. B The distribution of QRST angles. C The distribution of heart rate variance
Fig. 2Recovery time over left ventricular hypertrophy. Left ventricular hypertrophy is defined using the Cornell voltage product [20]
Association of ECG metrics with recovery time (RT) after dialysis
| Exposure | Model 1 | Model 2 | Model 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | RT Difference | 95% CI | P | N | RT Difference | 95% CI | P | N | RT Difference | 95% CI | P | |
| 242 | 4.1 | (−1.0, 8.3) | 0.1 | 242 | 5.1 | (−1.0, 9.4) | 0.06 | |||||
| 242 | 6.2 | (2.0, 11.6) | 0.009 | 242 | 6.2 | (1.0, 11.6) | 0.01 | |||||
| 221 | 1.0 | (−3.9, 5.1) | 0.9 | 221 | 1.0 | (−3.9, 6.2) | 0.8 | 221 | 0.0 | (−4.9, 5.1) | 0.9 | |
| 242 | −7.7 | (−21.3, 8.3) | 0.3 | 242 | −4.9 | (−19.7, 17.4) | 0.5 | 242 | −4.9 | (− 19.7, 12.7) | 0.6 | |
| 242 | −1.0 | (−3.0, 0.0) | 0.05 | 242 | −1.0 | (−3.0, 0.0) | 0.05 | 242 | −1.0 | (−2.0, 0.0) | 0.08 | |
| 242 | 12.7 | (−40.0, 113.8) | 0.7 | 242 | 16.2 | (−38.7, 120.3) | 0.6 | 242 | 10.5 | (−44.0, 118.1) | 0.8 | |
Model 1 includes the main exposure (one of the ECG measurements)
Model 2 includes model 1, age, sex, and race
Model 3 includes model 2, total depression score, LVMI, Charlson comorbidity index, serum ionized calcium, serum magnesium, and the use of antihypertensive medication
aFor left ventricular hypertrophy, Model 3 does not include LVMI